Abstract
The alteration of glycoprotein and glicolipids sialylation can cause increase in the serum concentration of sialic acid during the different pathological processes, including cancers and inflammatory diseases. The aim of this study was to determine the changes in the concentration of sialic acids in the serum of patients with pancreatic diseases. It has been shown a significant increase in the concentration of TSA, LSA and FSA in all pancreatic diseases in comparison to the healthy subjects, except the LSA in chronic pancreatitis. In contrast to the FSA, the TSA and LSA concentrations were significantly different between pancreatic diseases. There were no differences in sialic acids concentration according to the location of tumors in the pancreas and the severity of cancer. All sialic acids have a high diagnostic power in primary pancreatic cancers. The diagnostic sensitivity and specificity of LSA in cancers were comparable to that of CA19-9. These results indicate a possibility of TSA, LSA and FSA using in the diagnosis of pancreatic diseases. Among sialic acids, LSA has the greatest usefulness in the diagnosis and differentiation of pancreatic diseases. Its concentration can be useful in differentiating between pancreatic cancer and pancreatitis. The high diagnostic power of LSA, comparable with CA19-9, suggest the possibility of its use as a non-specific marker of pancreatic cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
